Bioactivity Of Opioidmimetic Substances
Bioactivity Of Opioidmimetic Substances
批准号:
7968153
负责人:
LAWRENCE H LAZARUS
金额:
$27.58万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Absence of pain sensationAcheAcuteAdamantaneAddictive BehaviorAdultAdverse effectsAffectAffinityAgonistAlcoholismAlcoholsAmazeAnalgesicsAnorexia NervosaAppearanceBioavailableBiological AssayBlood - brain barrier anatomyBlood specimenBone DensityBrainBulimiaCaviaCharacteristicsChildChronicClinicalComputersDataDevelopmentDietary intakeDiseaseEatingEating DisordersExhibitsFDA approvedFoodFutureGTP-Binding ProteinsGamblingHandHealthHumanImmuneIn VitroLeadLegal patentLeptinLigandsMalignant NeoplasmsMediatingMedicineMinorMorphineMorphine DependenceMulti-Drug ResistanceMusN,N-dimethyl-2&apos,6&apos-dimethyltyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acidNaloxoneNaltrexoneNarcotic AntagonistsNarcoticsNeuraxisObesityOpioidOpioid PeptideOpioid ReceptorOpioid Receptor BindingOverweightP-GlycoproteinPainPathogenesisPathway interactionsPerceptionPeripheralPharmaceutical ChemistryPharmaceutical PreparationsPhysiologicalPlayPopulationPost-Traumatic Stress DisordersPredispositionPreparationPropertyRewardsRiskRoleScientistSeriesSmokingSpinalStagingStressSymptomsSystemTailTelevisionTestingTherapeuticTraumaTwin Multiple BirthVas deferens structureVideo GamesWeight GainWithdrawal Symptomaddictionalcohol abuse therapyalcohol cravingalcoholism therapyanalogbaseclinically significantcravingdrug cravingfightingfood cravingileumin vivoinsightmeetingsmouse modelmu opioid receptorsneural circuitneurobehavioralnovelpeptide structurepleasurepreventpsychologicreceptorrelating to nervous systemresponsetrait
中文摘要
通过与吗啡(μ-阿片受体激动剂)和deltorpin(δ-阿片受体激动剂)比较,确定最近开发的阿片样物质的抗伤害感受(镇痛)和该活性的拮抗剂,以使用小鼠模型评估它们的作用模式。 抗伤害感受特征与体外功能药理学数据GPI(豚鼠回肠)和MVD(小鼠输精管)一致,并反映了阿片样物质受体结合亲和力,以及使用GTP-γ-S测定法评估G-蛋白相互作用,这代表了药理学制剂的体外分析。 一系列新型Dmt-Tic药理学药物或原型药物在体外和体内使用热板(脊髓上作用,中枢神经系统)和甩尾试验(脊髓作用)表现出拮抗作用。对照化合物表现出中枢(CNS)介导的镇痛作用,是口服生物可利用的阿片样物质。 有趣的是,N,N-二甲基-Dmt-Tic-NH-金刚烷和H-Dmt-Tic-NH-叔丁基衍生物抑制小鼠对吗啡的耐受性,这表明由于它们在体外抑制Pg-1,因此涉及多药耐药P-糖蛋白1。 其他Dmt-Tic化合物,例如MZ-2,特别是(专利申请待审)防止形成对吗啡的耐受性,如N-烯丙基-Dmtendomorphin类似物,其是吗啡或酒精治疗后的中性阿片样物质拮抗剂。 此外,耐受性的消除发生在没有纳洛酮和纳洛酮(FDA批准的用于治疗酒精中毒的药物)的严重副作用的情况下。N-烯丙基-Dmtendomorphin-1和-2衍生物是高度有效的μ-阿片类拮抗剂,如通过小鼠脑室内给药所证明的:它们有效地抑制吗啡抗伤害感受,类似于纳洛酮,一种标准的μ-阿片类受体拮抗剂。 这两种化合物都能有效地完全消除小鼠急性或慢性吗啡成瘾后的戒断症状。 此外,MZ-2减少了ob/ob小鼠的食物摄入量,改变了血液样本临床分析中肥胖的几个关键指标的水平,并提高了骨矿物质密度;这些数据预示着MZ-2在人类肥胖症中的应用。
英文摘要
Antinociception (analgesia) and antagonists to this activity by recently developed opioidmimetic substances was determined in comparison to morphine (mu-opioid receptor agonist) and deltorpin (delta-opioid agonist) to assess their mode of action using mice models. The antinociception profile paralleled that of the in vitro functional pharmacological data GPI (guinea-pig ileum) and MVD (mouse vas deferens) and reflected the opioid-receptor binding affinity in addition to the assessment of G-protein interaction using the GTP-gamma-S assays, which represent an in vitro analysis of the pharmacological preparations. A series of novel Dmt-Tic pharmacophoric drugs or protodrugs exhibited antagonism in vitro and in vivo using the hot-plate (supraspinal effects, the central nervous system) and tail-flick test (spinal effects). The control compounds exhibited central (CNS) mediated analgesia and were orally bioavailable opioidmimetics. Interestingly, N,N-dimethyl-Dmt-Tic-NH-adamantane and H-Dmt-Tic-NH--tert-butyl derivatives inhibited tolerance to morphine in mice, which suggests that the multidrug resistance P-glycoprotein 1 was involved due to their inhibition in vitro of Pg-1. Other Dmt-Tic compounds, such as MZ-2, in particular (patent application pending) prevents the formation of tolerance to morphine like the N-allyl-Dmtendomorphin analogues, which are neutral opioid antagonists following morphine or alcohol treatment. Furthermore, the elimination of tolerance occurred without the severe side-effects seen with both naloxone and naltrexone, a FDA approved drug for the treatment of alcoholism. N-allyl-Dmtendomorphin-1 and -2 derivatives were highly potent mu-opioid antagonists as demonstrated by intracerebroventricular administration in mice: they effectively inhibited morphine antinociception similar to naloxone, a standard mu-opioid receptor antagonist. Both compounds effectively and completely eliminated withdrawal symptoms following either acute or chronic morphine addiction in mice. In addition, MZ-2 decreased food intake in ob/ob mice, altered the levels of several key indicators of obesity in the clinical analyses of blood samples and elevated bone mineral density; the data portend an application of MZ-2 in fighting obesity in human populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MOLECULAR DYNAMICS CONFORMATION OF OPIOID PEPTIDES
-
批准号:6106788
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
MOLECULAR DYNAMICS CONFORMATION OF OPIOID PEPTIDES
-
批准号:6290083
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Bioactivity Of Neuropeptides
-
批准号:6838631
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Molecular Dynamics Conformation Of Opioid Peptides
-
批准号:7007485
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Bioactivity Of Opioidmimetic Substances
-
批准号:8149072
-
项目类别:
-
资助金额:$29.49万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Molecular Dynamics Conformation Of Opioid Peptides
-
批准号:7217694
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
MOLECULAR BIOLOGY OF OPIOID MEMBRANE RECEPTORS
-
批准号:6106802
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Molecular Dynamics Conformation Of Opioid Peptides
-
批准号:7328899
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Molecular Dynamics Conformation Of Opioid Peptides
-
批准号:7593970
-
项目类别:
-
资助金额:$29.75万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Molecular Dynamics Conformation Of Opioid Peptides
-
批准号:7734503
-
项目类别:
-
资助金额:$22.26万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
NEUROPEPTIDES--MOLECULAR MECHANISM OF ACTION
-
批准号:6432417
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
NEUROPEPTIDES--MOLECULAR MECHANISM OF ACTION
-
批准号:6106783
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Opioid Peptides--Molecular Mechanism Of Action
-
批准号:7328896
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Bioactivity Of Opioidmimetic Substances
-
批准号:7170022
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Opioid Peptides--Molecular Mechanism Of Action
-
批准号:8149062
-
项目类别:
-
资助金额:$29.49万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Bioactivity Of Opioidmimetic Substances
-
批准号:7328920
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Molecular Dynamics Conformation Of Opioid Peptides
-
批准号:6673258
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Bioactivity Of Neuropeptides
-
批准号:6673283
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Neuropeptides--molecular Mechanism Of Action
-
批准号:6838587
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
Neuropeptides--molecular Mechanism Of Action
-
批准号:6541000
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:LAWRENCE H LAZARUS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于无机基质固定碳点光学探针研究有机磷农药暴露AChE响应的活体测量
-
批准号:
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2024
-
负责人:冯锋
-
依托单位:
转录因子BMAL1调控AChE在昼夜节律紊乱致认知损害中的作用及分子机制
-
批准号:2024Y9230
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:姜雨
-
依托单位:
基于AChE/NLRP3 靶点研究垂穗石松中抗AD新型黄酮苷
吐星酸酯类成分的发现及作用机制研究
-
批准号:2024JJ8138
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:谭蕾红
-
依托单位:
基于GSK-3β/AChE双重抑制的抗AD杂交分子的设计、合成及作用机制研究
-
批准号:22367005
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:董永喜
-
依托单位:
基于可逆界面传质调控机制的AChE固定化荧光传感器及有机磷农药高灵敏抗干扰速测
-
批准号:32372427
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2023
-
负责人:冷远逵
-
依托单位:
利用微流体技术合成富缺陷MOFs材料定向捕获AChE酶构筑高性能传感界面
-
批准号:32302225
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:宋丹丹
-
依托单位:
抗基质干扰导向的AChE仿生荧光探针的设计合成及农药残留速测应用
-
批准号:--
-
项目类别:面上项目
-
资助金额:53万元
-
批准年份:2022
-
负责人:郝振霞
-
依托单位:
基于高分辨活性轮廓分析的中药AChE/GSK3β双靶点抑制剂高内涵筛选研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:翟蔓华芸
-
依托单位:
新型AChE/NLRP3双靶点抑制剂—藤石松中抗AD新颖黄酮苷吐星酸酯类成分的发现及作用机制研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:刘阳
-
依托单位:
基于AchE靶点的苗药三两银抗阿尔兹海默症甾体生物碱类化合物发现与作用机制研究
-
批准号:82260833
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:於祥
-
依托单位: